Table 3 QLQ-C30–global health status

From: Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)

Assessment time

TPF

PF

Treatment difference P -value

Baseline

61.5 (s.d.=1.69)

61.1 (s.d.=1.64)

0.8646

End of cycle 2

69.3 (s.d.=1.73)

66.8 (s.d.=1.75)

0.3290

End of cycle 4

70.7 (s.d.=1.91)

65.6 (s.d.=2.05)

0.0695

6 Months after RT

68.9 (s.d.=2.39)

59.4 (s.d.=2.73)

0.0092

  1. Abbreviations: QLQ-C30=Quality of Life Questionnaire C30; TPF=docetaxel, cisplatin, and 5-fluorouracil regimen; PF=cisplatin and 5-fluorouracil regimen; RT=radiotherapy.
Back to article page